The bioavailability of drugs from oral formulations is influenced by many physiological factors including gastrointestinal fluid composition, pH and dynamics, transit and motility, and metabolism and transport, each of which may vary with age, gender, race, food, and disease. Therefore, oral bioavailability, particularly of poorly soluble and/or poorly permeable compounds and those that are extensively metabolized, often exhibits a high degree of inter- and intra-individual variability. While several models and algorithms have been developed to predict bioavailability in an average person, efforts to accommodate intrinsic variability in the component processes are less common. An approach that incorporates such variability for human populations within a mechanistic framework is described together with examples of its application to drug and formulation development.

No abstract

The ultrafast kinetics of ligand exchange of cis-[Ru(bpy)(2)(CH(3)CN)(2)](2+) were measured in H(2)O and CH(3)CN. The formation of the (3)MLCT excited-state and a five-coordinate intermediate are observed in both solvents within 2 ps after excitation (310 nm, fwhm approximately 300 fs). The (3)MLCT excited-state undergoes vibrational cooling (5-6 ps), then decays to regenerate the ground-state with a lifetime of approximately 50 ps. In CH(3)CN, ligand recombination takes place in 28 ps, while the formation of cis-[Ru(bpy)(2)(CH(3)CN)(H(2)O)](2+) in H(2)O takes place with tau = 77 ps.

There is an increasing need to expand the structural diversity of the molecules investigated in lead-discovery programs. One way in which this can be achieved is by acquiring external datasets that will enhance an existing database. This paper describes a rapid procedure for the selection of external datasets using a measure of structural diversity that is calculated from sums of pairwise intermolecular structural similarities.